COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,871 Articles (22,568 medRxiv, 8,303 bioRxiv)

Most recent first Previous |  Page 1421: Articles 14201-14210  | Next

The impact of co-circulating pathogens on SARS-CoV-2/COVID-19 surveillance. How concurrent epidemics may decrease true SARS-CoV-2 percent positivity.
Kovacevic, A., Eggo, R. M., Baguelin, M., Domenech de Celles, M., Opatowski, L.
10.1101/2021.06.08.21258533 — Posted: 2021-06-12
Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Proteinco-immunization in rhesus macaques
Rosati, M., Agarwal, M., Hu, X., Devasundaram, S., Stellas, D., Chowdhury, B., Bear, J., Burns, R., Donohue, D., Pessaint, L., Andersen, H., Lewis, M. G., Terpos, E., Dimopoulos, M. A., Wlodawer, A., Mullins, J. I., Venzon, D. J., Pavlakis, G. N., Felber, B. K.
10.1101/2021.06.11.448032 — Posted: 2021-06-11
A combination of RBD and NTD neutralizing antibodies limits the generation of SARS-CoV-2 spike neutralization-escape mutants
Haslwanter, D., Dieterle, M. E., Wec, A. Z., O'Brien, C. M., Sakharkar, M., Florez, C., Tong, K., Rappazzo, C. G., Lasso, G., Vergnolle, O., Wirchnianski, A. S., Bortz, R. H., Laudermilch, E., Fels, J. M., Mengotto, A., Malonis, R. J., Georgiev, G. I., Quiroz, J., Wrapp, D., Wang, N., Dye, K. E., Barnhill, J., Dye, J. M., McLellan, J. S., Daily, J. P., Lai, J. R., Herbert, A. S., Walker, L., Chandran, K., Jangra, R. K.
10.1101/2021.06.10.447999 — Posted: 2021-06-11
B.1.1.7 and B.1.351 SARS-CoV-2 variants display enhanced Spike-mediated fusion
Rajah, M. M., Hubert, M., Bishop, E., Saunders, N., Robinot, R., Grzelak, L., Planas, D., Zivaljic, M., Planchais, C., Guivel-Benhassine, F., Porrot, F., Mouquet, H., Chakrabarti, L., Buchrieser, J., Schwartz, O.
10.1101/2021.06.11.448011 — Posted: 2021-06-11
Anti-SARS-CoV-2 hyperimmune immunoglobulin provides potent and robust neutralization capacity and antibody-dependent cellular cytotoxicity and phagocytosis induction through N and S proteins
Diez, J.-M., Romero, C., Cruz, M., Vandeberg, P., Merritt, W. K., Pradenas, E., Trinite, B., Blanco, J., Clotet, B., Willis, T., Gajardo, R.
10.1101/2021.06.11.447942 — Posted: 2021-06-11
High-affinity, neutralizing antibodies to SARS-CoV-2 can be made in the absence of T follicular helper cells
Chen, J. S., Chow, R. D., Song, E., Mao, T., Israelow, B., Kamath, K., Bozekowski, J., Haynes, W. A., Filler, R. B., Menasche, B. L., Wei, J., Alfajaro, M. M., Song, W., Peng, L., Carter, L., Weinstein, J. S., Gowthaman, U., Chen, S., Craft, J., Shon, J. C., Iwasaki, A., Wilen, C. B., Eisenbarth, S. C.
10.1101/2021.06.10.447982 — Posted: 2021-06-11
Predicted pH-dependent stability of SARS-CoV-2 spike protein trimer from interfacial acidic groups
Lobo, V. R., Warwicker, J.
10.1101/2021.06.06.447235 — Posted: 2021-06-11
A year of COVID-19 GWAS results from the GRASP portal reveals potential SARS-CoV-2 modifiers
Thibord, F., Chan, M. V., Chen, M.-H., Johnson, A. D.
10.1101/2021.06.08.21258507 — Posted: 2021-06-11
Adaptive vaccination may be needed to extirpate COVID-19: Results from a runtime-alterable strain-drift and waning-immunity model
Getz, W. M., Salter, R., Vissat, L. L., Koopman, J. S., Simon, C. P.
10.1101/2021.06.07.21258504 — Posted: 2021-06-11
Complement activation induces excessive T cell cytotoxicity in severe COVID-19
Georg, P., Astaburuaga-Garcia, R., Bonaguro, L., Brumhard, S., Michalick, L., Lippert, L. J., Kostevc, T., Gäbel, C., Schneider, M., Streitz, M., Demichev, V., Gemünd, I., Barone, M., Tober-Lau, P., Helbig, E. T., Stein, J., Dey, H.-P., Paclik, D., Mülleder, M., Aulakh, S. K., Mei, H. E., Schulz, A. R., Hippenstiel, S., Corman, V. M., Beule, D., Wyler, E., Landthaler, M., Obermayer-Wasserscheid, B., Boor, P., Demir, M., Wesselmann, H., Suttorp, N., Uhrig, A., Müller-Redetzky, H., Nattermann, J., Kuebler, W. M., Meisel, C., Ralser, M., Schultze, J. L., Aschenbrenner, A. C., Thibeault, C., Kurth, F., Sander, L.-E., Blüthgen, N., Sawitzki, B.
10.1101/2021.06.08.21258481 — Posted: 2021-06-11

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).